Insomnia in Patients with Impaired Kidney Function
Start with cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, followed by basic sleep hygiene measures and management of concurrent uremic symptoms; if these fail, consider low-dose gabapentinoids or simple sedatives with careful attention to renal dosing. 1, 2
Prevalence and Impact
Insomnia is extremely common in CKD, affecting approximately 60% of dialysis patients 1. This represents a substantially higher burden than the general population (33-50%) 3. The condition is associated with:
- Fatigue and poor health-related quality of life
- Depression
- Increased cardiovascular morbidity and mortality (particularly when combined with restless legs syndrome)
- Daytime dysfunction 1, 4
Primary Causes in Kidney Disease
The etiology is multifactorial and includes 4, 5:
- Uremia itself - direct metabolic effects on sleep architecture
- Concurrent symptoms: uremic pruritus (40% prevalence), restless legs syndrome (10-20%), nocturia
- Dialysis-related factors: frequent daytime napping during hemodialysis sessions, dialysis timing disrupting circadian rhythms
- Fluid overload contributing to sleep apnea
- Medications with stimulating or sedating effects
- Mood disorders: depression affects 22.8% of dialysis patients 1
- Poor sleep hygiene practices
Management Algorithm
Step 1: First-Line Treatment - CBT-I
Cognitive behavioral therapy for insomnia is the initial treatment for all patients with chronic insomnia, including those with CKD 2. This is a strong recommendation based on moderate-quality evidence from the American College of Physicians 2016 guideline—the most recent high-quality insomnia management guideline.
CBT-I components include 2:
- Sleep restriction therapy
- Stimulus control
- Cognitive therapy targeting sleep-related beliefs
- Sleep hygiene education
Delivery methods: in-person (individual or group), telephone-based, web-based modules, or self-help materials 2.
Step 2: Address Concurrent Symptoms
Systematically manage contributing uremic symptoms 1:
- Uremic pruritus: topical capsaicin, emollients for dry skin, gabapentinoids, or ultraviolet B therapy
- Restless legs syndrome: correct hyperphosphatemia and iron deficiency first; consider aerobic exercise, pneumatic compression; pharmacologically use low-dose gabapentinoids, levodopa, or nonergot dopamine agonists
- Nocturia: optimize fluid management and dialysis adequacy
- Depression: screen and treat appropriately
Step 3: Nonpharmacologic Interventions
Exercise and sleep hygiene measures 1:
- Regular aerobic exercise programs
- Avoid excessive daytime napping (particularly during dialysis sessions—this is a major contributor) 6
- Optimize bedroom environment: reduce noise and light exposure 6
- Remove stimulants (caffeine, nicotine)
- Consider dialysis regime modifications (longer nocturnal hemodialysis shows benefit) 7
Step 4: Pharmacologic Management (If CBT-I Fails)
Use shared decision-making to add short-term pharmacotherapy only after CBT-I has been unsuccessful 2. This is critical: the 2016 ACP guideline emphasizes CBT-I first, with medications as adjunctive therapy.
Medication Selection for CKD Patients:
Preferred agents in renal impairment 1:
Low-dose gabapentinoids (gabapentin, pregabalin)
- Dual benefit: treats insomnia AND uremic pruritus/restless legs syndrome
- Critical caveat: Requires dose adjustment for GFR; accumulation risk with standard dosing
- Highest level of evidence in CKD population 1
Simple sedatives (unspecified in KDIGO guideline, but general insomnia guidelines suggest):
- Short-intermediate acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) 3
- Ramelteon (melatonin receptor agonist)
- Use lowest effective dose
Sedating antidepressants (if comorbid depression/anxiety):
- Trazodone, mirtazapine preferred over tricyclics
- Avoid amitriptyline and doxepin in severe renal impairment due to anticholinergic burden
Critical Medication Warnings in CKD:
Avoid or use extreme caution 8:
- Tramadol and tapentadol: NOT recommended in GFR <30 mL/min/1.73 m² or ESRD
- Meperidine, codeine, morphine: Avoid in GFR <30 due to active metabolite accumulation
- Barbiturates and chloral hydrate: Not recommended for insomnia treatment 3
- OTC antihistamines, herbal supplements (valerian), melatonin: Not recommended due to lack of efficacy and safety data in chronic insomnia 3
Prescribing Principles 3:
- Start with lowest effective dose
- Follow patients every few weeks initially to assess effectiveness and side effects
- Educate about: treatment goals, safety concerns, side effects, drug interactions, potential for tolerance, rebound insomnia
- Attempt medication tapering when conditions allow (facilitated by concurrent CBT-I)
- Long-term use may be necessary for severe/refractory cases or chronic comorbid illness
- Dosing can be nightly, intermittent (3 nights/week), or as-needed
Common Pitfalls
Under-recognition: 41% of CKD patients report their care team never asked about sleep 9. Systematically screen using validated tools (Pittsburgh Sleep Quality Index).
Medication-first approach: Despite patient preference for nonpharmacologic strategies, 33% receive medications as first-line treatment 9. This contradicts evidence-based guidelines.
Inadequate dose adjustment: Standard dosing of renally-cleared medications (gabapentinoids, certain sedatives) leads to accumulation and toxicity.
Ignoring contributing factors: Treating insomnia without addressing uremic pruritus, restless legs syndrome, or dialysis-related napping is ineffective.
Polypharmacy: CKD patients are already on multiple medications; adding sedatives increases fall risk, cognitive impairment, and drug interactions.
Assuming transplant cures sleep problems: Sleep disturbances often persist post-transplant 7, 5.